LifeScience

eXmoor Pharma and Siam Bioscience Partner to Build Southeast Asia’s Premier Cell and Gene Therapy Hub

eXmoor Pharma, the integrated cell and gene therapy CDMO with embedded consultancy expertise, and Siam Bioscience, a leading biopharmaceutical company in A...

 September 24, 2025 | News

Akeso Doses First Patient in Phase II Study of Novel TIGIT/TGF-β Bifunctional Antibody for Pancreatic Cancer

Akeso Inc. has announced that the first patient has been dosed in its registrational Phase II study (AK130-202), evaluating AK130, a fully independent...

 September 23, 2025 | News

SOPHiA GENETICS Expands Collaboration with AstraZeneca to Advance AI-Powered Genomic Testing in Breast and Prostate Cancer

SOPHiA GENETICS an AI technology company transforming precision medicine announced an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq:...

 September 23, 2025 | News

Galux Validates AI-Driven Platform with Atomic-Level Precision in De Novo Antibody Design

Study confirms the novelty and atomic-level precision of de novo antibody design, including cryo-EM validation on a designed anti-PD-L1 antibody Finding...

 September 23, 2025 | News

Thermo Fisher Introduces Hypulse™ System to Transform XPS Depth-Profiling

Thermo Fisher Scientific, the world leader in serving science, has introduced the Thermo Scientific™ Hypulse™ Surface Analysis System. This inn...

 September 23, 2025 | News

CorestemChemon Phase 3 ALSummit Trial Shows Subgroup Benefit of Neuronata-R® in ALS

CorestemChemon Inc.  announced  that it has presented key findings from the Phase 3 ALSummit trial of Neuronata-R® (lenzumestrocel) an autolo...

 September 22, 2025 | News

Lenovo Launches GOAST v4.0 Slashing Genome Analysis to 24 Minutes with 3x Higher Throughput

Breakthrough high-performance computing solution delivers 3x higher throughput, cost efficiency, and faster life-saving discoveries Lenovo shared updates ...

 September 22, 2025 | News

EC Approves Alteogen’s EYLUXVI® as Eylea® Biosimilar for Major Ophthalmic Indications

EYLUXVI® is the second biosimilar approved for Alteogen following the launch of the Herceptin® biosimilar in China through it...

 September 18, 2025 | News

Mabwell and Aditum Bio Launch Kalexo Bio with $1 Billion siRNA Deal for Dyslipidemia and ASCVD

Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH) and Aditum Bio announced the launch of Kalexo Bio, a new company formed in conjunction with an exc...

 September 18, 2025 | News

Phrontline Biopharma Doses First Patient in Phase 1 Trial of TJ101, an EGFR/B7-H3 Antibody–Drug Conjugate

Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the first ...

 September 16, 2025 | News

BioAge Advances BGE-102 into Phase 1 Trials Triggering Milestone Payment to HitGen as DEL Technology Accelerates Drug Discovery

BGE-102, an orally available, brain-penetrant NLRP3 inhibitor, was developed from a hit compound identified using HitGen's industry-leading DEL technolog...

 September 16, 2025 | News

Alphamab Oncology’s NDA for KN026 Accepted by NMPA for HER2-Positive Gastric Cancer

Alphamab Oncology announced that the New Drug Application (NDA) for anbenitamab injection (KN026), independently developed by the Company and co-developed ...

 September 15, 2025 | News

Leads Biolabs Doses First Patient in Phase 1b/II Trial of Opamtistomig for Advanced Melanoma

Nanjing Leads Biolabs Co., announced the first patient has been successfully dosed in a Phase 1b/II clinical trial (NCT07099430) evaluating Opamt...

 September 15, 2025 | News

YolTech Raises $45 Million in Series B Funding to Propel In Vivo Gene-Editing Therapies

YolTech Therapeutics, a clinical-stage biotech company pioneering in vivo genome editing therapies, today announced the closing of its approximately $...

 September 12, 2025 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close